High Response Rates achieved in Lung Cancer in INSIGHT-003
Filed with ASX · · 3 pages · English
Story so far
Earlier from Immutep
- Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1
- Excellent Overall Survival in Head & Neck Cancer Patients
- Immutep Quarterly Activities Report Q3 FY25
- Immutep to Participate in Upcoming Investor Conferences
- First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
Later from Immutep
- Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer
- Primary Endpoint Met in Phase II Soft Tissue Sarcoma Trial
- Immutep’s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma
- Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases
- Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep